Merck KGaA’s Luciano Rossetti talks to In Vivo about the German pharma’s next wave of immuno-oncology products that are steadily moving through its pipeline, why GlaxoSmithKline PLC was an ideal IO partner in a very competitive cancer drug development arena and the company’s wider deal-making strategy when it comes to pipeline advancement.
In February 2019, Merck entered a global strategic alliance with GSK to jointly develop and commercialize its pipeline cancer therapy...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?